期刊文献+

HER2阳性浸润性乳腺癌X射线摄影微钙化特点 被引量:8

Features of X-ray mammographic microcalcifications in HER2 positive invasive breast cancer
原文传递
导出
摘要 目的X射线摄影微钙化征象在乳腺癌筛查、术前对病灶范围的评估以及治疗后的监测均有一定价值。目前,鲜见文献报道确定微钙化特征是否能够在浸润性乳腺癌中预测分子亚型。本研究通过总结HER2阳性乳腺癌X射线摄影表现的微钙化特点,研究其与其他分型浸润性乳腺癌的差异,指导临床通过X射线摄影表现预测乳腺癌分子分型。方法收集大连医科大学附属大连市中心医院2015-01-01-2017-12-31行手术治疗的浸润性乳腺癌且术前均行X射线摄影检查的患者225例,分为HER2阳性组61例和非HER2阳性组164例。对2组患者的X射线摄影微钙化特征进行记录、总结,包括是否存在微钙化、微钙化是否清晰、是局限性微钙化还是弥漫性微钙化,对比2组患者X射线摄影微钙化的特点。结果HER2阳性组X射线摄影特征与非HER2阳性组存在差异,HER2阳性组微钙化发生率为85.2%,高于非HER2阳性组的50.6%,差异有统计学意义,χ^2=18.088,P<0.001;HER2阳性组微钙化清晰比为88.0%,高于非HER2阳性组的37.3%,差异有统计学意义,χ^2=35.552,P<0.001;HER2阳性组弥漫性微钙化比例为52.0%,高于非HER2阳性组的9.6%,差异有统计学意义,χ^2=29.426,P<0.001。结论HER2阳性与非HER2阳性乳腺癌X射线摄影检查的微钙化特点具有一定的差异,HER2阳性浸润性乳腺癌微钙化更为常见,且其微钙化清晰的比例高、范围更广,对临床通过X射线摄影检查的微钙化特征预测浸润性乳腺癌分子分型有一定指导意义。 OBJECTIVE The characterization of x-ray mammographic microcalcifications are valuable in breast cancer screening and preoperative evaluation of disease extent as well as surveillance after treatment.There is no literature report on whether calcification characteristics can predict molecular subtypes in invasive breast cancer.We summarized the features of mammographic microcalcifications in HER2 positive breast cancer and investigated its difference with other molecular subtypes of invasive breast cancer in order to guide the clinical prediction of breast cancer molecular type by x-ray imaging.METHODS A total of 225 patients,from January 1,2015 to December 31,2017,who have undergone surgery and undergone x-ray examination preoperatively in Dalian Municipal Central Hospital Affiliated of Dalian Medical University were selected for research.They were divided into HER2 positive group(n=61)and non-HER2 positive group(n=164).The features of mammographic microcalcifications in the two groups were recorded and summarized,including if the microcalcification was present,whether the microcalcification was clear,localized or diffuse microcalcification.The differences in features of mammographic microcalcifications between the two groups were analyzed.RESULTS The x-ray features of HER2 positive group were different from those of the non-HER2 positive group.The incidence of microcalcification was higher in HER2 positive group than that in the non-HER2 positive group(85.2%vs 50.6%,χ^2=18.088,P<0.001).Microcalcification was clearer in HER2 positive group than that in the non-HER2 positive group(88.0%vs 37.3%,χ^2=35.552,P<0.001).The proportion of diffuse microcalcification was higher in HER2 positive group than that in the non-HER2 positive group(52.0%vs 9.6%,χ^2=29.426,P<0.001).CONCLUSIONS The x-ray microcalcification characteristics of HER2 positive and non-HER2 positive breast cancer are different.The microcalcification of HER2-positive breast cancer is more common,and more clear,and the range is wider.The finding may help
作者 姜雪 祖国 姜力群 郭文斌 JIANG Xue;ZU Guo;JIANG Li-qun;GUO Wen-bin(Dalian Municipal Central Hospital Affiliated of Dalian Medical University,Dalian 116033,P.R.China;Graduate School,Dalian Medical University,Dalian 116044 R.China)
出处 《中华肿瘤防治杂志》 CAS 北大核心 2019年第17期1280-1283,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺癌 X射线摄影钙化 分子分型 HER2阳性 breast cancer x-ray mammographic microcalcification molecular subtype HER2 positive
  • 相关文献

参考文献3

二级参考文献37

  • 1翁海莺,林月兰,徐学勤,陈克敏.乳腺良、恶性疾病钙化的X线表现分析[J].实用放射学杂志,2005,21(9):970-972. 被引量:27
  • 2廖瑜倩,徐兵河.118例小肿块多腋窝淋巴结转移乳腺癌患者的临床特征和预后分析[J].中华肿瘤杂志,2007,29(8):615-618. 被引量:14
  • 3Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA CancerJ Clin, 2015,65(2) :87-108. 被引量:1
  • 4Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies- improving the management of early breast cancer: St Gallen In- ternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015,26(8): 1533-1546. 被引量:1
  • 5National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Antiemesis, V. 3. 2015. Available at http://www, nccn. org/professionals /physician_gls/PDF/antiemesis. pdf. Accessed Au- gust 3,2015. 被引量:1
  • 6Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. AnnOncol, 2015,26(Suppl 5): v8-30. 被引量:1
  • 7Gonzalez-Angulo AM, Litton JK, Broglio KR, : High risk of recur renee for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller[J]. Clin Oncol, 2009, 27:5700 5706. 被引量:1
  • 8Rouanet P, Roger P, Rousseau E, et al. HER2 overexpression a major risk factor for recurrence in pTl~bNoM0 breast cancer: results from a French regional cohort[J]. Cancer Med, 2014,3 (1):134 142. 被引量:1
  • 9Gamucci T, Vaccaro A, Ciancola F, et al. Recurrence risk in small, node-negative, early breast cancer: a multicenter retro- spective analysis[J]. J Cancer Res Clin Oncol, 2013,139 (5) : 853-860. 被引量:1
  • 10Tryfonidis K, Zardavas D, Cardoso F. Small breast cancers: when and how to treat[J]. Cancer Treat Rev, 2014,40(10)z 1129-1136. 被引量:1

共引文献11

同被引文献63

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部